BNF eNewsletter

Email not displaying correctly? View it in your browser
Forward to a colleague | Sign up to the BNF newsletter

Newsletter

September 2019

Welcome to the September BNF Newsletter.

• One new drug monograph has been added to both BNF and BNFC in the last month: cefoxitin.
• One new drug monograph has been added to the BNF in the last month: chlormethine.
• We have included a dose change for typhoid vaccine to both the BNF and BNFC.
• We have also included MHRA advice on febuxostat (Adenuric®), rivaroxaban (Xarelto®), and tocilizumab (RoActemra®).

Kind regards,
BNF Team

Other topics:

Significant changes | Drug safety update | BNF 70 years | BNF offline | Feedback

Significant changes

BNF only

New monograph: Renoxitin® [cefoxitin] for complicated urinary tract infections and pyelonephritis.

New monograph: Ledaga® gel [chlormethine] for mycosis fungoides (initiated by a specialist).

New preparation: Imvaggis® [estriol] for vaginal atrophy in postmenopausal women.

Blinatumomab for treating acute lymphoblastic leukaemia in remission with minimal residual disease activity [NICE guidance].

Febuxostat (Adenuric®): increased risk of cardiovascular death and all-cause mortality in clinical trial in patients with a history of major cardiovascular disease [MHRA/CHM advice].

Fluocinolone acetonide intravitreal implant for treating recurrent non-infectious uveitis [NICE guidance].

Letermovir for preventing cytomegalovirus disease after a stem cell transplant [NICE guidance].

Migraine: updated guidance on management.

Rivaroxaban (Xarelto®): reminder that 15 mg and 20 mg tablets should be taken with food [MHRA/CHM advice].

Stroke: updated guidance on management.

BNFC Only

New monograph: Renoxitin® [cefoxitin] for complicated urinary tract infections and pyelonephritis.

Both BNF and BNFC

Nusinersen for treating spinal muscular atrophy [NICE guidance].

Tocilizumab (RoActemra®): rare risk of serious liver injury including cases requiring transplantation [MHRA/CHM advice].

Typhoid vaccine: updated guidance in-line with Public Health England recommendations.

Urinary-tract infections: updated guidance on management.

Dose Changes for both BNF and BNFC
Typhoid vaccine: booster dose added.

Drug Safety Update is a monthly newsletter from the MHRA and Commission on Human Medicine. Please follow this link to review the latest Drug Safety Update.

Carfilzomab (Kyprolis▼): reminder of risk of potentially fatal cardiac events.

Daratumumab (Darzalex▼): risk of reactivation of hepatitis B virus.

Naltrexone/bupropion (Mysimba): risk of adverse reactions that could affect ability to drive.

News

Celebrating 70 years of the BNF

We really appreciate the support you have given the BNF for our first 70 years and now, as part of our anniversary celebrations that are now underway, we want to showcase the rigorous editorial process that goes into creating the content that you rely on for your everyday practice. Want to know more?

Find out here

If you have a success story about how the BNF has been pivotal in your healthcare career we'd love to hear about it on social media! Just use the hashtag #BNF70years.

Looking for offline BNF access? Try the app

Specifically designed to help busy healthcare professionals access essential medicines information on-the-go, the BNF app provides an up-to-date offline reference to the BNF and BNFC, wherever and whenever you need.

Whether you are using Wi-Fi, a personal hotspot, 3G/4G/5G, or are without internet access, you can benefit from the same trusted app features and functionality, including:

• BNF and BNFC content
• Drug monographs (including indications and dose, cautions and side-effects)
• Interactions Checker tool
• Treatment summaries

Top tip
BNF and BNFC content is updated every month, to ensure up-to-date information is available and support safe and effective decision-making. Remember to get the most out of the app by connecting to the internet at least once a month to download the latest content.

Learn more about the BNF app

Please donate old copies of the BNF
The PharmAid Scheme is an initiative of the Commonwealth Pharmacists Association where recent versions of medicines information resources including the BNF are redistributed to low and middle income countries. You can make a difference in another commonwealth country by simply donating your old BNF copies to them.

For more information on this scheme see commonwealthpharmacy.org/what-we-do/pharmaid/. If you would like to donate your copy email: admin@commonwealthpharmacy.org.

How to purchase BNF

Print
To order the September 2019 edition, visit the Pharmaceutical Press website

Subscription
Purchase a print subscription, ensure access to the latest copy of BNF and save money

Online
BNF content is available via a subscription to MedicinesComplete

eBook
Access the latest copy of BNF on your mobile device, which is available as a PDF eBook

Newsletter Feedback
Please let us know if there are any issues that you'd like us to address in our newsletters. We welcome your feedback. If you have any comments or suggestions, please let us know at marketing@rpharms.com.

Terms of use

If you want to unsubscribe from emails from Pharmaceutical Press click here.

Pharmaceutical Press, 66-68 East Smithfield, London, E1W 1AW, United Kingdom.